Highlights

Well, I honestly was not really impressed with the data that they had shown [for Nerlynx], and it is a hard drug to give, it is an expensive drug, so it is a hard drug to get for a patient, their access is limited, and it is a hard drug to take. So, I just kind of felt that in the adjuvant, or extended adjuvant setting, I was never really excited about it, but I got less excited, so I am just kind of holding it in reserve possibly for metastatic disease.

Well, 100% of patients are going to get Herceptin at some point. The only paradigm that has really changed was after the KATHERINE study came out. So, when we were treating neoadjuvantly, and then patients had residual disease afterwards, we did not quite know how to treat those patients, and a lot of them just continued on Herceptin for the year. But after the KATHERINE data, I would say most people are switched over to using Kadcyla, so that is the only difference. After the APHINITY trial too, where people were using Perjeta and Herceptin adjuvantly, or if they had residual disease after neoadjuvant, they would kind of keep them on Perjeta and Herceptin, which never made any sense to me because I was like they still have disease, why are you treating them with the same drugs? So, then after the KATHERINE data came out, I think that has been dropped, and people are going to Kadcyla.